Non-regulatory Press releases
PILA PHARMA: UPCOMING PARTICIPATION IN OBESITYWEEK AND AMERICAN HEART ASSOCIATION CONVENTION
Malmö, 27 October 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, informs of its participation in two upcoming scientific conferences in the United States. 04-07 November: ObesityWeek® by The Obesity Society (TOS)Atlanta, United Stateshttps://obesityweek.org/ 07-10 November: American Heart Association® Convention (AHA) New Orleans, United Stateshttps://professional.heart.org/en/meetings/scientific-sessions…
PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES
Malmö, 07 October 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space that CEO Gustav H. Gram has increased his shareholding in the company. Mr. Gram acquired a total of 36,677 shares in PILA PHARMA AB…
PILA PHARMA TO PARTICIPATE AT THE 61ST EASD DIABETES & OBESITY SCIENTIFIC MEETING, NEXT WEEK 16-19 SEPTEMBER IN VIENNA
Malmö, 08 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space, of the participation at the 2025 annual congress, hosted by the European Association for Studies of Diabetes (EASD). PILA PHARMA CEO Gustav…
PILA PHARMA: ALL H1 REPORT & INVESTOR INTERVIEWS NOW ONLINE
Malmö, 08 September 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space, of the recordings from the last few weeks activities and presentations. 10X Podcast (Recording - Stockholm, Sweden)Recorded Wednesday 27 August 11:00 CET (ENGLISH)CEO…
PILA PHARMA: H1 REPORT INTERVIEW RECORDING WITH DIREKT STUDIOS – CEO COMMENTS ON HEAVILY OVERSUBSCRIBED RIGHTS ISSUE AND PLANS
Malmö, 29 August 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, informs investors and others with interest in the space of the participation in H1 report review with Direkt Studios. CEO Gustav H. Gram was live with Direkt Studios at 13:30 CEST on August 27,…